The ability of sorafenib to suppress tumor angiogenesis has been well established and is likely due to the potent inhibition of the proangiogenic vascular endothelial growth factor receptor (VEGFR1)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor-ß [9]. This evidence concerns the gene KDR and neoplasm.